

ASX RELEASE

Apiam Animal Health Limited (ASX: AHX)

Apiam to present at Coffee Microcaps Morning Webinar Series

Melbourne, May 7, 2020 – Apiam Animal Health Limited (**Apiam** or the **Company**) today announced its Managing Director, Dr Chris Richards will present at the Coffee Microcaps Morning Webinar Series.

Coffee Microcaps provides a platform to connect ASX Microcaps companies from outside the resources and life sciences sector to present and connect with ASX microcap investors, both institutional and retail.

The webinar will be recorded and available for viewing on the <u>Coffee Microcaps YouTube</u> Channel 3 business days after the webinar.

Apiam's presentation for the investor conference is also attached to this announcement.

--Ends--

For further information, please contact:

Dr Chris Richards
Managing Director
Apiam Animal Health Limited
chris@apiam.com.au

Catherine Ross / Kyahn Williamson WE Buchan 0421 997 481 apiam@we-worldwide.com

Authorisation

This announcement was authorised by the Board of Directors of Apiam Animal Health Ltd.

About Apiam Animal Health Limited

Apiam Animal Health is positioned in the Australian market as a vertically integrated animal health business providing a range of products and services to Production and Mixed animals. Apiam Animal Health's strategy is to service Production and Mixed animals throughout their lifecycle, including the provision of veterinary services, ancillary services, genetics, wholesale and retail of related products, together with technical services related to food-chain security.






Apiam Animal Health – company snapshot

- Unique established veterinary group that listed in December 2015 to fund acquisition of some of Australia's largest rural veterinary practices
- Oiversified & robust business model with a rural and regional focus
 - vertically integrated model across entire animal health value chain
 - 46 locations across large production animal areas of Australia
 - servicing whole spectrum of production & companion animals
 - new complementary and high-growth opportunities such as Zoono disinfectant product distribution, ProDairy consulting & specialised diagnostics
- Successfully executing 3-year plan to build process & capacity, grow animal numbers and leverage products and services across large footprint
- Strong long-term industry outlook for regional production & companion animal sectors
- Attractive financial profile with revenue growth, gross margin expansion and strong operating cash flows

AHX : snapshot	A\$
Share price (1 May 2020)	0.47
Market cap (1 May 2020)	\$54.8M
Revenue (FY19)	111.7
EBITDA underlying (FY19)	10.0
NPAT underlying (FY19)	4.0
Net debt (as at 31 Dec 2019)	35.9M
Ownership by Board & Mgt	~ 28%







Resilient vet services portfolio with high growth opportunities



companion animal clinics

technicians

Employover 150 veterinarians and







Veterinary Services International export Product sales **Genetics & Ancillary** Veterinary, animal well-being and Veterinary service programs Genetics sourcing, sales and production services supported by technical products related consulting services provided in 10+ countries Quality assurance services to Service the whole animal spectrum In-house warehousing and logistics including biosecurity and food - beef feedlot, pigs, dairy and services safety plans companion animals (including Diagnostic lab services & equine) Product distribution agreements autogenous vaccines including Zoono disinfectant 46 clinics locations technologyagreement Sheep consulting & parasitology diagnostics JV with PETstock for some Private label products

Integrated online platform

Veterinary consulting services


- Development of new markets for year-round genetic services
- US Joint Venture for distribution of specialised swine products
- Chinese sheep genetics, consultancy and export agreement
- Autogenous vaccine export opportunities

Core veterinary business

High growth complementary business initiatives

Diversified geographic exposure

Veterinary services across Australia




- 46 locations across Australia
- Over 150 veterinarians
- Clinics generally located in regional areas with high concentrations of production animals and agricultural operations
- Diversified services and products spread across various species, geographies, commodities and markets
- Acquisition strategy focused on businesses with a new attractive regional exposure or specialist expertise

Financial performance across key metrics

Revenue (\$m) - (FY17 - FY20 YTD)



Gross profit (\$m) - (FY17 - FY20 YTD)




- · Resilient revenue growth over past 3 years despite challenging industry conditions in many agricultural areas
- Targeted change in Apiam business mix to focus on higher value products & services driving strong gross margin improvement in face of broader industry challenges
- FY20 YTD (up to 31 March) performing strongly as new product and service lines delivering growth in face of COVID-19 challenges, as well as recent improvements in underlying agricultural conditions

LEVERAGING PERFORMANCE

Strategic Focus





- ✓ Integrated systems
- √ Roll-out of practice management systems



Animal numbers

- ✓ Business unit synergies
 - ✓ Acquisition pipeline
- √ Satellite clinic program



Services, product range & margins

- ✓ Private label strategy
 - ✓ New products
- ✓ New service programs

Building the foundations

Gaining efficiencies

Leveraging performance

Service & product range expansion in FY20

July 2019

Launch of Best Mates Wellness Program (recurring revenue model)



August 2019

Launch of ProDairy consultancy program





October 2019

Acquisition of ACE Laboratory Services (highly specialized service offering)

March 2020

COVID-19 business continuity product & service extensions

December 2019

Acquisition of Grampians Animal Health (includes specialised sheep consulting services)





November 2019

Entered into new distribution agreement with Zoono Animal Health for Zoono (ASX: ZNO) disinfectant nanotechnology





November 2019

Acquisition of Devoted Vets at Warragul Vic.



COVID-19 business continuity

Comprehensive response to COVID-19 to ensure continuity to meet client needs

Companion animal services


- Implementation of strict clinic guidelines & protocol steps with new service offerings
- Modified clinic service
- Kerbside service
- Telemedicine service (launched in April) www.furlifevet.com.au
- Home service (in emergency settings only)

Agricultural & livestock services


- Deployment of a new remote consulting technology (live-stream)
- Allows vets to visually inspect health of herds in conjunction with farm personnel (allowing distance)
- Assists with on-going monitoring on a more efficient basis
- Expect to be on-going in the industry, particularly for large production animal customers


Companion animal clinics continued to trade strongly in March and April 2020, reflective of the success of implemented response











Proprietary sanitizer and disinfectant, effective against COVID-19

- Exclusive distribution agreement for use in livestock, agriculture and veterinary in Australia and US
- Provides ongoing mechanical activity for up to 30 days with over 150 tests by third- party laboratories world-wide for human and animal use
- Demonstrated effectiveness against bacteria and viruses including COVID-19, H1N1 influenza, African Swine Fever (99.99% efficacy)
- Offer range of products including the Z-71 Microbe Shield which can be applied to surfaces via fogging or spraying
- TGA approved in Australia for COVID-19, bacteria and germs on hard surfaces

Surge in demand with broadening applications & geographies

- Strong interest from pig, poultry and veterinary industries resulting in material contribution from launch of product sales in March FY20.
- Successful trials in USA pig industry with effective prevention against porcine epidemic diarrhea virus (PEDv) outbreaks in endemic nursery sites (porcine coronavirus)
- Registration and distribution partners in Vietnam and Philippines on track for Q1FY2021
- New customers & applications since COVID-19 outbreak have included veterinary clinics, offices, equine facilities, pet food plants, feed mills, vehicles, and pet stores.

ProDairy consultancy & product supply service

Innovative subscription model offering dairy farmers an end-to-end service:



Animal Health Programs

Staff Training



Direct ordering capability


Risk management & planning



Performance analysis reports

Client Assistance Programs

- Full marketing campaign was launched in April 2020 across targeted radio, social media and television
- ~10% of Victoria's dairy cows are subscribed to the program
- Strategy to increase market penetration in Apiam's other geographic areas






Best Mates companion animal program

Wellness program to drive recurring growth in animal services

- Whole of life health and wellness program drives loyalty
- Successful targeted clinic launch program in July 2019 has been expanded in FY20 across company footprint
- Average member growth of 17.7% per month since launch with strong growth continuing through March & April despite COVID-19
- · Members pay an annual subscription charge


Best Mate members (# weekly)





Summary & outlook

- Apiam is delivering growth in core business as agricultural conditions improve
 - Recent rainfall and improved commodity prices across all segments are positive for H2 FY20 outlook
 - Global shortage of meat protein supporting growth in animal numbers
- New business lines delivering strong financial contributions, as improved animal biosecurity practices and COVID-19 business practices has increased
- Acquisitions made in H1 FY20 performing in-line with expectations
- Strong Q3 FY20 performance
 - Q3 FY20 (Jan-Mar) revenue +16.2% (vs pcp) & gross profit +29.5% (vs pcp)
 - Q3 FY20 YTD (Jul-Mar) revenue +5.4% (vs pcp) & gross profit +13.4% (vs pcp)
- Apiam expect to deliver EBIT growth in H2 FY20 (vs H1 FY20)
- Dividend paid for H1FY20



Apiam investment highlights



Robust and diversified business model underpinning growth across market cycles

High growth & complementary business initiatives introduced in areas of consulting, diagnostics and innovative product technologies

Strong cash generation in place to enable Apiam's growth strategy & maintenance of dividends

Highly experienced Board & Management team

Favourable long-term industry outlook for Australia's production and companion animal sectors



Disclaimer

DISCLAIMER

The information presented to you by Apiam Animal Health Limited ACN 604 961 024 (Company) in this presentation and any related documents (together, Materials) has been prepared for information purposes only and is not an offer or invitation to acquire or dispose of shares in the Company, nor shall it be relied on in connection with any investment decision.

NO FINANCIAL ADVICE

The information contained in the Materials has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Nothing in the Materials constitutes as financial advice. Before making any investment decision, you should consider, with or without the assistance of a financial advisor, whether an investment is appropriate in light of your particular investment needs, objective and financial circumstances.

NO LIABILITY

The Company has prepared the Materials based on information available to it at the time of preparation, from sources believed to be reliable and subject to the qualifications in the Materials. To the maximum extent permitted by law, the Company, its related bodies corporate and their respective officers, employees, representatives, agents or advisers accept no responsibility or liability for the contents of the Materials. No representation or warranty, express or implied, is made as to the fairness, accuracy, adequacy, validity, correctness or completeness of the information, opinions and conclusions contained in the Materials.

PAST PERFORMANCE

Past performance information contained in the Materials is given for illustration purposes only and should not be relied upon as (and is not) an indication of future performance. Actual results could differ materially from those referred to in the Materials.

FORWARD LOOKING STATEMENTS

The Materials contain certain 'forward looking statements'. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results, performance or achievement of the Company to be materially different from future results, performance or achievements expressed or implied by those statements.

These statements reflect views only as of the date of the Materials. The actual results of the Company may differ materially from the anticipated results, performance or achiev ement expressed, projected or implied by these forward looking statements. Subject to any obligations under the Corporations Act, the Company disclaims any obligation to disseminate any updates or revision to any forward looking statement to reflect any change in expectations in relation to those statements or any change in circumstances, events or conditions on which any of those statements are based.

While the Company believes that the expectations reflected in the forward looking statements in the Materials are reasonable, neither the Company nor any other person gives any representation, assurance or quarantee that the occurrence of the events expressed or implied in any forward looking statements in the Materials will actually occur and you are cautioned not to place undue reliance on any forward looking statements.